Sarepta Therapeutics Inc (NASDAQ:SRPT)
Stock Price:
$130.19
+1.81
(1.41%)
Updated
Mar 24, 2023 08:00 PM GMT+0000
| Market Cap | 11.45B |
|---|---|
| Revenue | 0.93B |
| Gross Profit | 793.02M |
| Shares Out | 87.98M |
| EPS (ttm) | -8.03 |
| PE Ratio | -16.2822 |
| Forward PE | -26.0717 |
| Dividend Rate (ttm) | 0.0000 |
| Dividend Yield | 0.0000 |
| Trading Day | Mar 24 |
|---|---|
| Last Price | $130.19 |
| Previous Close | $128.38 |
| Change ($) | 1.81 |
| Change (%) | 1.41% |
| Day's Open | 128.97 |
| Day's Range | 126.99 - 130.54 |
| Day's Volume | 0.97M |
| 52 Week Range | 61.28 - 159.84 |
About Sarepta Therapeutics Inc
Sarepta Therapeutics Inc. is leading a revolution in precision genetic medicine and every day is an opportunity to change the lives of people living with raredisease.
The Company has built an impressive position in Duchenne muscular dystrophy (DMD) and in gene therapies for limb-girdle muscular dystrophies (LGMDs), mucopolysaccharidosis type IIIA, Charcot-Marie-Tooth (CMT), and other CNS-related disorders, with more than 40 programs in various stages of development. The Company's programs and research focus span several therapeutic modalities, including RNA, gene therapy and gene editing.
News
No news found.Quick info
Country
United States
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Employees
840
CEO
Douglas Ingram
Address
215 1st St Ste 415
Cambridge
Massachusetts
02142-1213
Cambridge
Massachusetts
02142-1213
Phone
16172744000
Website
www.sareptatherapeutics.com
Ticker Symbol
SRPT
Exchange
NASDAQ Stock Exchange
Reporting Currency
USD
Sarepta Therapeutics Inc income statements (2022) (USD)
| August 2022 | August 2022 | May 2022 | March 2022 | |
|---|---|---|---|---|
| Total Revenue | 233.49M | 233.49M | 210.83M | 701.89M |
| Cost of Revenue | 37.80M | 37.80M | 31.44M | 97.05M |
| Gross Profit | 195.69M | 195.69M | 179.39M | 604.84M |
| Research & Development | 252.33M | 252.33M | 194.25M | 771.18M |
| Selling General & Admin | 154.32M | 154.32M | 71.84M | 282.66M |
| Operating Expense | 444.62M | 444.62M | 297.71M | 1.15B |
| Operating Income | -211.13M | -211.13M | -86.88M | -449.71M |
| Other Income Expense Net | 0 | 0 | 0 | 0 |
| EBIT | -211.13M | -211.13M | -86.88M | -449.71M |
| Interest Income | 13.62M | 13.62M | 0 | 63.17M |
| Pretax Income | -228.09M | -228.09M | -104.15M | -418.95M |
| Income Tax | 3.39M | 3.39M | 879K | -168K |
| Minority Interest | 0 | 0 | 0 | 0 |
| Net Income | -231.48M | -231.48M | -105.03M | -418.78M |
| Net Income Basic | -231.48M | -231.48M | -105.03M | -418.78M |
Sarepta Therapeutics Inc income statements (2021) (USD)
| November 2021 | August 2021 | May 2021 | March 2021 | |
|---|---|---|---|---|
| Total Revenue | 189.41M | 164.09M | 146.93M | 540.10M |
| Cost of Revenue | 23.44M | 19.52M | 22.35M | 63.38M |
| Gross Profit | 165.96M | 144.57M | 124.59M | 476.72M |
| Research & Development | 139.12M | 239.62M | 195.15M | 722.34M |
| Selling General & Admin | 61.13M | 72.35M | 71.13M | 317.88M |
| Operating Expense | 223.86M | 331.66M | 288.80M | 1.10B |
| Operating Income | -34.46M | -167.57M | -141.87M | -564.16M |
| Other Income Expense Net | 0 | 0 | 0 | 0 |
| EBIT | -34.46M | -167.57M | -141.87M | -564.16M |
| Interest Income | 0 | 15.78M | 15.59M | 56.98M |
| Pretax Income | -47.91M | -81.76M | -167.39M | -553.07M |
| Income Tax | 237K | -354K | -143K | 1.06M |
| Minority Interest | 0 | 0 | 0 | 0 |
| Net Income | -48.14M | -81.41M | -167.25M | -554.13M |
| Net Income Basic | -48.14M | -81.41M | -167.25M | -554.13M |
Sarepta Therapeutics Inc income statements (2020) (USD)
| November 2020 | June 2020 | March 2020 | March 2020 | |
|---|---|---|---|---|
| Total Revenue | 143.92M | 137.36M | 113.67M | 113.67M |
| Cost of Revenue | 15.02M | 19.82M | 19.15M | 19.15M |
| Gross Profit | 128.91M | 117.55M | 94.52M | 94.52M |
| Research & Development | 190.44M | 184.32M | 131.97M | 131.97M |
| Selling General & Admin | 75.37M | 71.58M | 80.58M | 80.58M |
| Operating Expense | 280.99M | 275.72M | 231.70M | 231.70M |
| Operating Income | -137.07M | -138.35M | -118.03M | -118.03M |
| Other Income Expense Net | 0 | -12.45M | 100.65M | 100.65M |
| EBIT | -137.07M | -138.35M | -118.03M | -118.03M |
| Interest Income | 13.77M | 13.71M | 13.62M | 13.62M |
| Pretax Income | -196.4M | -150.8M | -17.38M | -17.38M |
| Income Tax | 96K | 20K | 115K | 115K |
| Minority Interest | 0 | 0 | 0 | 0 |
| Net Income | -196.5M | -150.82M | -17.49M | -17.49M |
| Net Income Basic | -196.5M | -150.82M | -17.49M | -17.49M |
Sarepta Therapeutics Inc income statements (2019) (USD)
| December 2019 | September 2019 | June 2019 | March 2019 | |
|---|---|---|---|---|
| Total Revenue | 100.11M | 99.04M | 94.67M | 87.01M |
| Cost of Revenue | 15.77M | 13.25M | 16.14M | 12.28M |
| Gross Profit | 84.35M | 85.79M | 78.53M | 74.73M |
| Research & Development | 222.94M | 133.95M | 113.27M | 90.55M |
| Selling General & Admin | 81.42M | 75.43M | 67.39M | 60.57M |
| Operating Expense | 320.13M | 222.63M | 196.80M | 163.40M |
| Operating Income | -220.02M | -123.59M | -102.13M | -76.39M |
| Other Income Expense Net | -14.97M | -2.51M | -174.1M | -172K |
| EBIT | -220.02M | -123.59M | -102.13M | -76.39M |
| Interest Income | 8.39M | 7.52M | 7.43M | 7.34M |
| Pretax Income | -234.99M | -126.1M | -276.23M | -76.56M |
| Income Tax | 711K | 226K | 174K | 84K |
| Minority Interest | 0 | 0 | 0 | 0 |
| Net Income | -235.7M | -126.33M | -276.4M | -76.64M |
| Net Income Basic | -235.7M | -126.33M | -276.4M | -76.64M |
Sarepta Therapeutics Inc income statements (2018) (USD)
| December 2018 | September 2018 | June 2018 | March 2018 | |
|---|---|---|---|---|
| Total Revenue | 84.42M | 78.49M | 73.53M | 64.60M |
| Cost of Revenue | 13.35M | 8.96M | 6.95M | 5.80M |
| Gross Profit | 71.06M | 69.53M | 66.58M | 58.81M |
| Research & Development | 142.41M | 86.58M | 122.85M | 46.20M |
| Selling General & Admin | 64.22M | 53.04M | 49.38M | 43.34M |
| Operating Expense | 219.98M | 148.59M | 179.18M | 95.34M |
| Operating Income | -135.56M | -70.1M | -105.65M | -30.74M |
| Other Income Expense Net | -6.11M | -6.97M | -3M | -4.49M |
| EBIT | -135.56M | -70.1M | -105.65M | -30.74M |
| Interest Income | 7.25M | 10.68M | 8.15M | 7.63M |
| Pretax Income | -141.67M | -77.07M | -108.65M | -35.22M |
| Income Tax | -779K | -674K | 622K | 139K |
| Minority Interest | 0 | 0 | 0 | 0 |
| Net Income | -140.9M | -76.39M | -109.27M | -35.36M |
| Net Income Basic | -140.9M | -76.39M | -109.27M | -35.36M |
Sarepta Therapeutics Inc income statements (2017) (USD)
| December 2017 | September 2017 | June 2017 | |
|---|---|---|---|
| Total Revenue | 57.28M | 45.95M | 35.01M |
| Cost of Revenue | 3.76M | 3.86M | 2.31M |
| Gross Profit | 53.52M | 42.10M | 32.71M |
| Research & Development | 44.44M | 34.23M | 58.80M |
| Selling General & Admin | 31.98M | 28.17M | 31.88M |
| Operating Expense | 80.18M | 66.26M | 92.99M |
| Operating Income | -22.9M | -20.31M | -57.98M |
| Other Income Expense Net | -2.94M | -25.42M | -5.18M |
| EBIT | -22.9M | -20.31M | -57.98M |
| Interest Income | 2.69M | N.A | N.A |
| Pretax Income | -25.84M | -45.72M | -63.16M |
| Income Tax | -1.84M | 2.01M | -109K |
| Minority Interest | 0 | 0 | 0 |
| Net Income | -24M | -47.73M | -63.05M |
| Net Income Basic | -24M | -47.73M | -63.05M |
Sarepta Therapeutics Inc balance sheet (2022) (USD)
| August 2022 | August 2022 | May 2022 | March 2022 | |
|---|---|---|---|---|
| Current Cash | 1.93B | 1.93B | 2.01B | 2.12B |
| Receivables | 230.28M | 230.28M | 197.20M | 171.64M |
| Inventory | 208.10M | 208.10M | 199M | 186.21M |
| Current Assets | 2.47B | 2.47B | 2.53B | 2.60B |
| Other Current Assets | 102.91M | 102.91M | 121.32M | 130.38M |
| Short Term Investments | 102.91M | 102.91M | 121.32M | 130.38M |
| Long Term Investments | 527.55M | 527.55M | 525.21M | 543.88M |
| Property/Plant Equipment | 183.29M | 183.29M | 187.25M | 191.16M |
| Good Will | N.A | N.A | N.A | N.A |
| Intangible Assets | 13.06M | 13.06M | 13.33M | 14.24M |
| Tangible Assets (Net) | 713.40M | 713.40M | 843.56M | 0.91B |
| Other Assets | 232.47M | 232.47M | 235.60M | 248.15M |
| Total Assets | 3B | 3B | 3.06B | 3.15B |
| Accounts Payable | 56.21M | 56.21M | 54.01M | 76.74M |
| Other Current Liabilities | 489.36M | 489.36M | 400.96M | 375.99M |
| Total Current Liabilities | 545.57M | 545.57M | 454.96M | 452.73M |
| Total Liabilities | 2.27B | 2.27B | 2.20B | 2.22B |
| Long Term Debt | 1.10B | 1.10B | 1.10B | 1.10B |
| Current Long Term Debt | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 |
| Common Stock | 87.51M | 87.51M | 87.25M | 81.26M |
| Treasury Stock | 0 | 0 | 0 | 0 |
| Retained Earnings | -3.54B | -3.54B | -3.31B | -3.21B |
| Capital Surplus | N.A | N.A | N.A | N.A |
| Shareholder Equity | 726.46M | 726.46M | 856.89M | 0.93B |
| Other Liabilities | N.A | N.A | N.A | N.A |
Sarepta Therapeutics Inc balance sheet (2021) (USD)
| November 2021 | August 2021 | May 2021 | March 2021 | |
|---|---|---|---|---|
| Current Cash | 1.60B | 1.73B | 1.74B | 1.94B |
| Receivables | 181.56M | 148.26M | 136.37M | 138.58M |
| Inventory | 288.47M | 268.76M | 240.33M | 231.96M |
| Current Assets | 2.19B | 2.27B | 2.27B | 2.49B |
| Other Current Assets | 116.17M | 120.92M | 156.82M | 176.08M |
| Short Term Investments | 116.17M | 120.92M | 156.82M | 176.08M |
| Long Term Investments | 476.91M | 493.86M | 493.88M | 499.52M |
| Property/Plant Equipment | 199.25M | 203.33M | 203.11M | 190.43M |
| Good Will | N.A | N.A | N.A | N.A |
| Intangible Assets | 14.20M | 14.11M | 14.12M | 13.63M |
| Tangible Assets (Net) | 455.32M | 471M | 521.32M | 748.13M |
| Other Assets | 146.19M | 154.27M | 161.63M | 155.59M |
| Total Assets | 2.66B | 2.76B | 2.77B | 2.98B |
| Accounts Payable | 44.16M | 76.68M | 76.65M | 111.09M |
| Other Current Liabilities | 329.28M | 348.34M | 288.09M | 304.94M |
| Total Current Liabilities | 373.44M | 425.02M | 364.74M | 416.03M |
| Total Liabilities | 2.19B | 2.27B | 2.23B | 2.22B |
| Long Term Debt | 1.09B | 1.09B | 1.09B | 0.99B |
| Current Long Term Debt | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 |
| Common Stock | 79.88M | 79.75M | 79.45M | 77.96M |
| Treasury Stock | 0 | 0 | 0 | 0 |
| Retained Earnings | -3.08B | -3.04B | -2.96B | -2.85B |
| Capital Surplus | N.A | N.A | N.A | N.A |
| Shareholder Equity | 469.53M | 485.11M | 535.45M | 761.76M |
| Other Liabilities | N.A | N.A | N.A | N.A |
Sarepta Therapeutics Inc balance sheet (2020) (USD)
| November 2020 | June 2020 | March 2020 | March 2020 | |
|---|---|---|---|---|
| Current Cash | 1.82B | 1.64B | 1.76B | 1.76B |
| Receivables | 124.89M | 104.03M | 106.88M | 106.88M |
| Inventory | 220.12M | 179.65M | 173.17M | 173.17M |
| Current Assets | 2.32B | 2.46B | 2.55B | 2.55B |
| Other Current Assets | 161.57M | 111.38M | 93.09M | 93.09M |
| Short Term Investments | 161.57M | 421.35M | 406.94M | 406.94M |
| Long Term Investments | 457.99M | 42.91M | 43.26M | 43.26M |
| Property/Plant Equipment | 171.72M | 227.54M | 200.42M | 200.42M |
| Good Will | N.A | N.A | N.A | N.A |
| Intangible Assets | 13.34M | 13.11M | 12.81M | 12.81M |
| Tangible Assets (Net) | 878.70M | 1.04B | 1.14B | 1.14B |
| Other Assets | 192.28M | 140.07M | 143.54M | 143.54M |
| Total Assets | 2.78B | 2.88B | 2.95B | 2.95B |
| Accounts Payable | 74.53M | 91.66M | 26.60M | 26.60M |
| Other Current Liabilities | 303.86M | 263.24M | 279.83M | 279.83M |
| Total Current Liabilities | 378.39M | 354.90M | 306.43M | 306.43M |
| Total Liabilities | 1.89B | 1.84B | 1.80B | 1.80B |
| Long Term Debt | 700.47M | 766.56M | 753.22M | 753.22M |
| Current Long Term Debt | 0 | N.A | N.A | N.A |
| Minority Interest | 0 | 0 | 0 | 0 |
| Common Stock | 3.55B | 78.43M | 77.96M | 77.96M |
| Treasury Stock | 0 | N.A | N.A | N.A |
| Retained Earnings | -2.66B | -2.46B | -2.31B | -2.31B |
| Capital Surplus | N.A | 3.51B | 3.46B | 3.46B |
| Shareholder Equity | 892.05M | 1.04B | 1.14B | 1.14B |
| Other Liabilities | N.A | N.A | N.A | N.A |
Sarepta Therapeutics Inc balance sheet (2019) (USD)
| December 2019 | September 2019 | June 2019 | March 2019 | |
|---|---|---|---|---|
| Current Cash | 835.08M | 724.83M | 808.59M | 732.19M |
| Receivables | 90.88M | 68.03M | 56.98M | 50.51M |
| Inventory | 171.38M | 166.36M | 156.57M | 140.47M |
| Current Assets | 1.47B | 1.36B | 1.43B | 1.67B |
| Other Current Assets | 78.85M | 75.96M | 73.30M | 79.18M |
| Short Term Investments | 289.67M | 324.06M | 294.48M | 612.02M |
| Long Term Investments | 41.50M | 41.40M | 41.62M | 38.56M |
| Property/Plant Equipment | 167.55M | 159.03M | 156.65M | 147.38M |
| Good Will | N.A | N.A | N.A | N.A |
| Intangible Assets | 12.50M | 11.98M | 11.83M | 11.78M |
| Tangible Assets (Net) | 800.18M | 0.98B | 1.08B | 1.33B |
| Other Assets | 132.36M | 127.77M | 110.25M | 94.75M |
| Total Assets | 1.82B | 1.70B | 1.75B | 1.96B |
| Accounts Payable | 68.09M | 81.95M | 44.05M | 26.50M |
| Other Current Liabilities | 188.83M | 126.31M | 110.88M | 110.87M |
| Total Current Liabilities | 264.77M | 215.86M | 162.09M | 137.37M |
| Total Liabilities | 1B | 707.27M | 648.59M | 615.33M |
| Long Term Debt | 729.62M | 486.16M | 481.25M | 477.92M |
| Current Long Term Debt | N.A | N.A | N.A | N.A |
| Minority Interest | 0 | 0 | 0 | 0 |
| Common Stock | 75.18M | 74.50M | 74.33M | 74.13M |
| Treasury Stock | N.A | N.A | N.A | N.A |
| Retained Earnings | -2.29B | -2.06B | -1.93B | -1.66B |
| Capital Surplus | 3.11B | 3.05B | 3.03B | 3B |
| Shareholder Equity | 818.19M | 1B | 1.10B | 1.35B |
| Other Liabilities | N.A | N.A | N.A | N.A |
Sarepta Therapeutics Inc balance sheet (2018) (USD)
| December 2018 | September 2018 | June 2018 | March 2018 | |
|---|---|---|---|---|
| Current Cash | 370.83M | 209.70M | 410.38M | 557.23M |
| Receivables | 49.04M | 48.60M | 42.99M | 39.85M |
| Inventory | 125.45M | 115.82M | 104.13M | 99.38M |
| Current Assets | 1.43B | 1.01B | 1.14B | 1.22B |
| Other Current Assets | 62.39M | 54.80M | 42.99M | 31.20M |
| Short Term Investments | 803.08M | 583.16M | 538.77M | 491.76M |
| Long Term Investments | 32.74M | 31M | 1M | 784K |
| Property/Plant Equipment | 97.02M | 76.84M | 57.62M | 53.93M |
| Good Will | N.A | N.A | N.A | N.A |
| Intangible Assets | 11.57M | 15.32M | 14.86M | 14.47M |
| Tangible Assets (Net) | 1.02B | 618.99M | 679.09M | 757.63M |
| Other Assets | 74.55M | 47.66M | 34.43M | 11.68M |
| Total Assets | 1.64B | 1.18B | 1.25B | 1.30B |
| Accounts Payable | 33.83M | 20.41M | 17.38M | 17.38M |
| Other Current Liabilities | 139.56M | 93.99M | 77.27M | 69.43M |
| Total Current Liabilities | 173.69M | 114.39M | 104.69M | 91.20M |
| Total Liabilities | 609.80M | 543.06M | 548.11M | 523.52M |
| Long Term Debt | 420.55M | 415.45M | 429.93M | 427.37M |
| Current Long Term Debt | N.A | N.A | 9.51M | 3.45M |
| Minority Interest | 0 | 0 | 0 | 0 |
| Common Stock | 71.07M | 66.69M | 66.35M | 65.49M |
| Treasury Stock | N.A | N.A | N.A | N.A |
| Retained Earnings | -1.58B | -1.44B | -1.36B | -1.25B |
| Capital Surplus | 2.61B | 2.08B | 2.06B | 2.03B |
| Shareholder Equity | 1.03B | 639.85M | 699.05M | 776.76M |
| Other Liabilities | N.A | N.A | N.A | N.A |
Sarepta Therapeutics Inc balance sheet (2017) (USD)
| December 2017 | September 2017 | June 2017 | |
|---|---|---|---|
| Current Cash | 599.69M | 617.63M | 168.35M |
| Receivables | 29.47M | 24.75M | 17.79M |
| Inventory | 83.61M | 64.69M | 41.75M |
| Current Assets | 1.23B | 735.61M | 390.59M |
| Other Current Assets | 36.51M | 28.53M | 30.09M |
| Short Term Investments | 479.37M | N.A | 132.60M |
| Long Term Investments | 10.76M | 784K | 784K |
| Property/Plant Equipment | 43.16M | 38.87M | 39.39M |
| Good Will | N.A | N.A | N.A |
| Intangible Assets | 14.36M | 14.03M | 7.80M |
| Tangible Assets (Net) | 770.72M | 679.37M | 367.12M |
| Other Assets | 11.05M | 10.99M | 11.58M |
| Total Assets | 1.31B | 800.28M | 450.14M |
| Accounts Payable | 8.47M | 5.32M | 10.92M |
| Other Current Liabilities | 72.75M | 60.42M | 43.82M |
| Total Current Liabilities | 88.33M | 70.47M | 65.96M |
| Total Liabilities | 518.75M | 103.13M | 72.37M |
| Long Term Debt | 424.88M | 26.55M | N.A |
| Current Long Term Debt | 6.18M | 4.73M | 11.22M |
| Minority Interest | 0 | 0 | 0 |
| Common Stock | 64.79M | 64.57M | 55.34M |
| Treasury Stock | N.A | N.A | N.A |
| Retained Earnings | -1.22B | -1.19B | -1.15B |
| Capital Surplus | 2.01B | 1.89B | 1.52B |
| Shareholder Equity | 789.22M | 697.16M | 377.77M |
| Other Liabilities | N.A | N.A | N.A |
Sarepta Therapeutics Inc cash flow (2022) (USD)
| November 2022 | August 2022 | |
|---|---|---|
| Net Income | -257.74M | -231.48M |
| Depreciation | 14.37M | 11.75M |
| Changes in Receivables | 223.45M | 230.28M |
| Changes in Inventories | 221.19M | 208.10M |
| Cash Change | 2.07B | 1.93B |
| Cash Flow | -64.96M | -66.82M |
| Capital Expenditures | -8.23M | -9.08M |
| Investments | N.A | N.A |
| Investing Activity (other) | N.A | N.A |
| Total Investing Cash Flows | 19.12M | -289.99M |
| Dividends Paid | N.A | N.A |
| Net Borrowings | -638.52M | -0.93B |
| Other Financing Cash Flows | N.A | N.A |
| Cash Flow Financing | 216.43M | 339K |
| Exchange Rate Effect | N.A | N.A |
Sarepta Therapeutics Inc cash flow (2021) (USD)
| November 2021 | |
|---|---|
| Net Income | -48.14M |
| Depreciation | 14.58M |
| Changes in Receivables | 181.56M |
| Changes in Inventories | 288.47M |
| Cash Change | 1.60B |
| Cash Flow | -703.36M |
| Capital Expenditures | -9.24M |
| Investments | N.A |
| Investing Activity (other) | N.A |
| Total Investing Cash Flows | 20.27M |
| Dividends Paid | N.A |
| Net Borrowings | -620.37M |
| Other Financing Cash Flows | N.A |
| Cash Flow Financing | 5.90M |
| Exchange Rate Effect | N.A |
Sarepta Therapeutics Inc cash flow (2020) (USD)
| November 2020 | June 2020 | March 2020 | |
|---|---|---|---|
| Net Income | -196.5M | -150.82M | -17.49M |
| Depreciation | 19.62M | 9.71M | 8.68M |
| Changes in Receivables | 17.80M | 2.85M | -16M |
| Changes in Inventories | 40.47M | -6.48M | -1.79M |
| Cash Change | -245.2M | -124.25M | 0.93B |
| Cash Flow | 282M | -107.6M | 627.79M |
| Capital Expenditures | -53.59M | -19.17M | -9.12M |
| Investments | N.A | -14.32M | -115.44M |
| Investing Activity (other) | N.A | -735K | -1.19M |
| Total Investing Cash Flows | 2.17M | -34.23M | -17.68M |
| Dividends Paid | N.A | N.A | N.A |
| Net Borrowings | -1.28B | N.A | N.A |
| Other Financing Cash Flows | N.A | N.A | -4.8M |
| Cash Flow Financing | 355.39M | 17.58M | 319.02M |
| Exchange Rate Effect | N.A | N.A | N.A |
Sarepta Therapeutics Inc cash flow (2019) (USD)
| December 2019 | September 2019 | June 2019 | March 2019 | |
|---|---|---|---|---|
| Net Income | -235.7M | -126.33M | -276.4M | -76.64M |
| Depreciation | 8.21M | 8.28M | 7.69M | 6.37M |
| Changes in Receivables | -22.85M | -11.05M | -6.47M | -1.47M |
| Changes in Inventories | -5.02M | -9.79M | -16.1M | -15.02M |
| Cash Change | 110.25M | -83.66M | 79.66M | 366.56M |
| Cash Flow | -168.13M | -67.43M | -79M | -146.23M |
| Capital Expenditures | -18.29M | -10.02M | -17.28M | -17.12M |
| Investments | 35.37M | -7.94M | 342.21M | 152.35M |
| Investing Activity (other) | N.A | N.A | N.A | N.A |
| Total Investing Cash Flows | 17.08M | -17.96M | 152.37M | 135.23M |
| Dividends Paid | N.A | N.A | N.A | N.A |
| Net Borrowings | 244.94M | N.A | N.A | N.A |
| Other Financing Cash Flows | 4.34M | -3.45M | -889K | N.A |
| Cash Flow Financing | 261.30M | 1.73M | 6.29M | 377.56M |
| Exchange Rate Effect | N.A | N.A | N.A | N.A |
Sarepta Therapeutics Inc cash flow (2018) (USD)
| December 2018 | September 2018 | June 2018 | March 2018 | |
|---|---|---|---|---|
| Net Income | -140.9M | -76.39M | -109.27M | -35.36M |
| Depreciation | 3.53M | 3.59M | 2.87M | 2.25M |
| Changes in Receivables | -443K | -5.62M | -3.14M | -10.38M |
| Changes in Inventories | -9.63M | -11.69M | -4.75M | -15.77M |
| Cash Change | 161.13M | -200.67M | -147M | -42.46M |
| Cash Flow | -122.42M | -113.32M | -117.25M | -35.67M |
| Capital Expenditures | -20.76M | -21.17M | -9.58M | -12.84M |
| Investments | -216.98M | -42.23M | -45.51M | -1.42M |
| Investing Activity (other) | N.A | N.A | N.A | N.A |
| Total Investing Cash Flows | -237.74M | -63.4M | -55.09M | -14.26M |
| Dividends Paid | N.A | N.A | N.A | N.A |
| Net Borrowings | 827K | -30.61M | 3.61M | -5.17M |
| Other Financing Cash Flows | -144K | -1.99M | N.A | N.A |
| Cash Flow Financing | 521.28M | -23.96M | 25.35M | 7.47M |
| Exchange Rate Effect | N.A | N.A | N.A | N.A |
Sarepta Therapeutics Inc cash flow (2017) (USD)
| December 2017 | September 2017 | June 2017 | |
|---|---|---|---|
| Net Income | -24M | -47.73M | -63.05M |
| Depreciation | 2.12M | 2.56M | 1.77M |
| Changes in Receivables | -4.72M | -6.96M | -5.51M |
| Changes in Inventories | -18.91M | -22.94M | -11.31M |
| Cash Change | -17.94M | 449.28M | -106.38M |
| Cash Flow | -31.06M | -57.9M | -85.15M |
| Capital Expenditures | -4.52M | -7.76M | -3.23M |
| Investments | -489.17M | 132.70M | 83.52M |
| Investing Activity (other) | N.A | N.A | N.A |
| Total Investing Cash Flows | -493.7M | 124.95M | -20.05M |
| Dividends Paid | N.A | N.A | N.A |
| Net Borrowings | -15.73M | 20.59M | -2.51M |
| Other Financing Cash Flows | 519.10M | N.A | N.A |
| Cash Flow Financing | 506.81M | 382.24M | -1.17M |
| Exchange Rate Effect | N.A | N.A | N.A |
Sarepta Therapeutics Inc dividends (USD)
Total Valuation
Sarepta Therapeutics Inc has a market cap or net worth of $11.45 billion. The enterprise value is $11.01 billion.
Market Cap
11.45B
Enterprise Value
11.01B
Important Dates
Earnings Date
May 3, 2023
Ex-Dividend Date
n.a
Share Statistics
Sarepta Therapeutics Inc has 87.98 million shares outstanding.
Shares Outstanding
87.98M
Float
n.a
Valuation Ratios
The trailing PE ratio is -16.2822 and the forward PE ratio is -26.0717. Sarepta Therapeutics Inc's PEG ratio is 0.2913.
PE Ratio
-16.2822
Forward PE
-26.0717
PS Ratio
12.2800
PB Ratio
29.7600
PEG Ratio
0.2913
Stock Price Statistics
The stock price has increased by 0.0047%. The beta is 0.9328, so Sarepta Therapeutics Inc's price volatility has been lower than the market average.
Beta (1Y)
0.9328
52-Week Price Change
+0.0047%
50-Day Moving Average
132.85
200-Day Moving Average
120.88
Average Volume (30 Days)
2.35M
Income Statement
In the last 12 months, Sarepta Therapeutics Inc had revenue of $0.93 billion and earned $793.02 million in profits. Earnings per share was $-8.03.
Revenue
0.93B
Gross Profit
793.02M
EBITDA
-535.49M
Earnings per Share
-8.03
About
Ticker Symbol
SRPT
Reporting Currency
USD
Key Executives
Toshav Bracha Ephrat
Sr VP & General Counsel
Mahatme Sandesh
EVP, CFO & CBO
JOHNSON GRAHAM
Sr VP Preclinical Dev & Rsrch
JACOBSEN MICHAEL A
VP of Finance and PAO
OHANLEY PETER D
Sr. Vice President
O'Neill Gilmore Neil
SVP & Chief Medical Officer
FORREST K MICHAEL
Outside Director
MILE MELINDA G
Controller and PAO
Aphale Jayant
VP, Technical Operations